{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-028015","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.896254+00:00","generated_at":"2026-06-23T04:27:18.154576+00:00","sec_items":["1.01","2.01","2.03","3.02","3.03","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GBS acquires Intelligent Fingerprinting for stock; expands non-invasive drug testing","bullets":["Acquired IFP for 2,963,091 common shares + 2,363,003 Series C preferred; up to 1,649,273 additional preferred reserved.","IFP's 10-min fingerprint sweat test detects opioids, cocaine, methamphetamines, benzodiazepines, marijuana; over 200 customers.","Board increased to 7 members; Jason Isenberg and David Jenkins appointed as directors.","Preferred shares convertible into 3 common shares, subject to shareholder approval; 12-month lock-up on issued shares.","GBS to file TGA application for IFP's CE Mark in Australia; IFP's UK ISO 13485 facility complements GBS Australia facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-028015","json":"https://secwatch.observer/filing/0001493152-22-028015.json","markdown":"https://secwatch.observer/filing/0001493152-22-028015.md","text":"https://secwatch.observer/filing/0001493152-22-028015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:27:18.154576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a10b6e76ec","claim":"Jason Isenberg was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..","evidence_excerpt":"each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"db2d0c90bc","claim":"David Jenkins was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..","evidence_excerpt":"each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}